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This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation and            
management of pulmonary sarcoidosis, with each section summarised with key clinical practice            
points. In an era in which medical practice is increasingly determined by evidence-based guidelines,              
it must be acknowledged from the outset that current evidence in sarcoidosis, especially with regard               
to treatment, is weak. Thus, a number of the conclusions in this Statement are based on expert                 
opinion and accumulated clinical experience.  
 
The diagnosis of pulmonary sarcoidosis is often challenging, with ongoing evolution in clinician views              
on the need for a tissue diagnosis. Historically, a biopsy diagnosis was considered mandatory and               
we provide guidance on when to offer bronchoscopy and which bronchoscopic procedure to             
perform. We also stress that decisions made by individual patients to decline bronchoscopy, when              
there is a highly probable but not definite clinical diagnosis, should be supported in most cases, with                 
careful subsequent monitoring. The document includes sections on the diagnosis of cardiac            
sarcoidosis and pulmonary hypertension as either disorder may present to respiratory physicians as             





Traditional treatment algorithms and their reported application in the medical literature tend to be              
based on a ‘one size fits all’ approach and this has often led to over-treatment and major                 
steroid-related comorbidity. However, a great many patients do not need to be treated: the broad               
indications for initiating therapy are a) a high risk of mortality or disability due to major organ                 
involvement; and b) unacceptable loss of quality of life. In this statement, we focus on the                
management of pulmonary disease; the management of concurrent cardiac sarcoidosis or           
pulmonary hypertension requires referral to expert sub-specialist teams.  
 
Key pulmonary management considerations are discussed in this statement. Whilst higher dose            
treatment regimens may be required in high-risk disease, a highly flexible patient-centred approach             
is essential when treatment is introduced solely for quality of life reasons. In this context, sustained                
high-dose therapy is usually inappropriate. Patients should be asked to weigh-up treatment benefits             
against adverse effects before longer-term treatment decisions are made, with the danger of             
important comorbidities arising from long-term treatment kept carefully in mind. Monitoring must            
be tailored to specific goals. Fatigue, a highly prevalent and often disabling symptom in sarcoidosis,               




decision-making and this, in turn, requires attention to clear communication, discussed in the final              
part of this statement. Finally, it is important to note that in a few areas of diagnosis and                  
management where there was a non-unanimous consensus amongst the statement authors, this is             




The Statement covers diagnosis and management of pulmonary sarcoidosis. Reference is also made             
to 
diagnosis of cardiac sarcoidosis and pulmonary hypertension as either disorder may present to             
respiratory physicians as ‘symptomatic pulmonary sarcoidosis’. Other extra pulmonary sarcoidosis          
diagnoses are not covered by this Statement and it is recommended that specialists with specific               
sarcoidosis knowledge be consulted when the disease is present outside the chest. Importantly, it              
may be difficult to identify the true extent of organ involvement leading to underestimation of               








The Clinical Statement Group (CSG) was chaired by Dr Muhunthan Thillai and Professor Athol Wells.               
Membership was drawn from respiratory medicine, nursing, radiology and included lay/patient           
input. The CSG identified key areas requiring Clinical Practice Points. The overall content was              
developed to reflect the scope approved by the BTS Standards of Care Committee (SOCC). Following               
discussions of broad statement content, individual sections were drafted by group members. A final              
edited draft was reviewed by the BTS SOCC before posting for public consultation and peer review                
on the 
BTS website November 2019. The revised document was re-approved by the BTS SOCC in March               
2020 before final publication.  
 
A summary of Clinical Practice points is provided in Box 1. 
Box 1 






1. The respiratory examination in pulmonary sarcoidosis is often normal, and is an unreliable              
measure of disease extent or morbidity. 
2. Pulmonary function tests are often normal in non-fibrotic sarcoidosis, and may not reflect              
disease activity or symptom burden. 
3. Screening for extra-thoracic disease is important. At baseline, patients should have a full              
blood count, biochemical tests (including urea and electrolytes, liver function tests,           
calcium), serum ACE levels (non-unanimous consensus) and a 12-lead ECG.  
4. In patients with eye symptoms, a baseline ophthalmic review should be undertaken by              
either an optician or an ophthalmologist (depending on the severity of symptoms). 
5. Patients should be asked routinely about fatigue and mood disturbance. 
6. A 
comprehensive exposure and occupational history should be taken to exclude both           
berylliosis and silicosis which can present in a similar manner to sarcoidosis. 
 
Cardiac sarcoidosis and pulmonary hypertension 
1. Cardiac sarcoidosis and/or pulmonary hypertension should be considered in all patients            
with pulmonary sarcoidosis who have levels of breathlessness which are disproportionate to            
their lung function impairment. 
2. Baseline testing in all patients with suspected cardiac sarcoidosis (i.e. those with ECG 
abnormalities, cardiac symptoms or breathlessness out of context with their pulmonary 




suggest cardiac sarcoidosis should be confirmed with​ Cardiac magnetic resonance imaging ( 
CMR) or ​positron emission tomography (​PET). 
3. All patients with palpitations should be offered a 24 hour Holter monitor. 
4. In patients with pulmonary sarcoidosis, the presence of cardiac involvement, based on             
advanced imaging (cardiac MRI or PET) findings, should be confirmed by a multidisciplinary             
team with experience in both sarcoidosis and other forms of cardiac disease. There is a               
current initiative to identify tertiary ILD centres that have immediate access to specialist             




patients with suspected sarcoidosis should have a CXR. If they have typical findings on a radiograph                
with a typical clinical presentation (eg in the context of Lofgren’s disease) then a CT scan may not be                   
necessary as long as patients are followed up in clinic with a repeat CXR within 3 months and a CT                    
scan performed if circumstances change. 
2. Multi-disciplinary review of chest imaging is recommended for all patients with a non-typical              
clinical presentation or CT appearance to determine the need for a confirmatory bronchoscopy or              
biopsy. 
3. When performing a bronchoscopy, patients with predominantly lymph node disease should            
undergo an EBUS whereas those with predominantly parenchymal disease should have           
transbronchial biopsies. If both nodal and parenchymal disease is present, EBUS is the preferred              




4. All patients should be part of the decision making process when deciding on whether a biopsy is                  
necessary or whether it is safe to follow them up in the clinic alone, with a view to revisiting the                    
need for a biopsy if circumstances change. 
 
Management 
1. There is often a fine line to making the decision to start pharmacological treatment and                
all patients should be fully informed and be at the heart of this decision making process. 
2. Whilst there is no good evidence for any drug regimen in sarcoidosis, the majority of                
patients needing treatment should initially be treated with steroids ranging from 10mg            
prednisolone per day in long-standing and insidiously progressive disease, up to 20-40mg            
per day in more acute disease. A maintenance dose of 5-10 mg after these initial doses for                 
6-12 months is usual. 
3. Most patients who need treatment should be offered methotrexate (administered orally,            
or subcutaneously) as the first choice of second line agent. 
4. Referral for lung transplantation should be considered in all patients with advanced             
pulmonary fibrosis and associated pulmonary hypertension. 
5. All patients with sarcoidosis related fatigue should have a systematic approach to             
diagnosis of the cause of fatigue and management initiated as appropriate. 
6. In line with other chronic lung conditions, patients should be offered smoking cessation              





Monitoring​, ​discharge and withdrawal of treatment 
1. No patients on medication should be managed in primary care alone, even stable  
well patients should have hospital monitoring when on treatment. Patients under the long 
term care of their GP should be referred back to a hospital respiratory physician if they 
develop new or worsening symptoms. 
2. All patients undergoing active monitoring or treatment should have regular lung function 
tests as part of routine care. 
3. A trial of withdrawal of steroid therapy should be performed in most patients with 
controlled disease after 6-12 months on medication. 
 
Communication 
1. Clinicians should consider the possible need for benefits advice, occupational therapy           
home assessment, pulmonary rehabilitation referral as well as GP assistance with palliative            
care if needed e.g. in cases of progressive fibrotic pulmonary sarcoidosis with resulting             
respiratory failure.  
2. All patients should be encouraged to complete an inventory of quality of life measures               
and as part of this clinicians should emphasise the concept of `self-care` i.e. a deliberate               





3. There should be good communication between service providers (both between tertiary            
and secondary care, and between different specialists depending on organ involvement)           






2. Clinical presentation  
 
Lung involvement in pulmonary sarcoidosis 
 
Sarcoidosis can affect almost any organ (Figure 1). Pulmonary involvement, including thoracic lymph             
node disease and/or parenchymal disease is the most commonly affected site, occurring in over 90%               
of cases (1-3). Bilateral hilar and right paratracheal lymphadenopathy is a classical presentation for              
sarcoidosis, although isolated bilateral hilar lymphadenopathy is more frequent (4). Granulomatous           
inflammation most often occurs along lymphatic tracks: thus, peribronchial tissue and interlobular            
septa are the most common sites of sarcoid lesions. Pleural disease is uncommon (5) but should be                 
considered in the setting of a lymphocytic effusion with other pulmonary features of the disease.               
Rarely, sarcoidosis affects the upper airways, including the trachea and larynx (6). Severe lower              
airway inflammation can result in fibrotic stenosis and distortion. (6) Pneumothoraces are a             




Isolated thoracic lymphadenopathy is usually asymptomatic and may be incidentally detected on            
imaging, as part of a screening program or after ​non-specific presenting symptoms such as              
persistent cough. In Scandinavia, a region with a high incidence of sarcoidosis, a large percentage of                
patients have incidental disease, with over half of all patients having Scadding stage I appearances               
on chest x-ray (8, 9) (see Table 1). In a study of incidental findings on chest CT imaging, a histological                    
diagnosis of sarcoidosis was made in 22% of patients with at least one enlarged mediastinal lymph                
node (≥10mm on short axis) (10).  
Clinical history and examination 
Most patients with node-limited disease are asymptomatic. However, some may present with            
systemic symptoms (fevers, night sweats, fatigue, weight loss, diffuse myalgias). Bilateral hilar            
lymphadenopathy (BHL) may accompany sarcoid uveitis, or parotitis. Löfgren’s syndrome consists of            




Patients with parenchymal sarcoidosis often present with chest symptoms, depending upon the            
extent of lung involvement (1, 11). Dyspnoea and cough are presenting features in approximately              
30% of patients (2). Exertional dyspnoea tends to be mild early in disease (1, 12). Non-cardiac chest                 
pain is often characterised by chest tightness or pleuritic discomfort (13). Systemic symptoms,             
including fatigue, are variably present when pulmonary sarcoidosis is diagnosed. Pulmonary fibrosis            
in sarcoidosis usually develops in long-standing, previously recognised disease, but is occasionally            
apparent at presentation. Cough and exertional dyspnoea are common in advanced sarcoidosis (14)             
and tend to be associated with sputum production when there is co-existing bronchiectasis or              
aspergillus infection (15).  
It is important to take an accurate exposure and occupational history to exclude conditions which               
may present in a similar manner including berylliosis (e.g. those in the aerospace or defence               
industry) and silicosis (e.g. those working in the mining, quarrying or stonemasonry industry).  
The respiratory examination is almost always normal, both in node-limited sarcoidosis and in             




involvement. Classical ‘end-inspiratory’ crackles are not a typical feature of sarcoidosis but may             
occur in fibrotic sarcoidosis. Clubbing is uncommon (16).  
 
Hypoxaemia is present only in patients with extensive fibrotic disease and/or pulmonary            
hypertension (17). Pulmonary function tests may be normal, restrictive, obstructive or show an             
isolated reduction in gas transfer. Airway hyperresponsiveness is present in approximately 20% of             
patients, usually associated with endobronchial involvement (18). In patients with fibrotic pulmonary            
disease, physiologic derangements are more severe and an obstructive ventilatory defect is more             
frequent (19).  
 
Indications for diagnostic biopsy are discussed in section five. Biochemical tests are often unhelpful              
for diagnosis, but may serve as markers of treatment responsiveness or the need for treatment (e.g.                
hypercalcaemia). All patients should have a full blood count, serum calcium, liver function             
monitoring and an ECG. Specialist opinions should be sought if there is major extrapulmonary organ               
involvement. Specifically, ophthalmic review is appropriate in any patient with ocular symptoms ​(20)             




skin lesions. These opinions should be sought in parallel with management of pulmonary sarcoidosis              
as in some instances treatment modalities may be similar for multiple organ involvement. 
 
All ​patients should have serum ACE estimation in order to identify patients in whom elevated levels                
are a marker of active disease and are potentially helpful during follow-up (non-unanimous             
consensus). 24 hour urinary Calcium estimation should not be performed in all patients but only in                
those with a history of renal calculi (non-unanimous consensus). In addition to basic biochemical              
tests, patients should have serum calcium measured at baseline. Whilst patients with sarcoidosis             
may have low serum levels of 25-OH-cholecalciferol (vitamin D3), serum 1,25-(OH)2-cholecalciferol           
may be elevated due to granuloma macrophages overexpressing 1-alpha-hydroxylase which can lead            
to hypercalcaemia or hypercalciuria. If vitamin D supplementation is being considered because of             
deficiency or to protect bone health during oral steroid therapy, this should be carried out carefully                
with regular monitoring of serum and urinary calcium levels to identify and prevent significant              
complications of vitamin D therapy including life-threatening hypercalcaemia, renal stones and, in            






Fatigue and mood disturbance 
 
Fatigue is present in up to 80% of sarcoidosis patients, regardless of organ involvement (21), and is                 
often difficult to manage, with a significant negative impact on patient-reported quality of life (21).               
The aetiology may be multifactorial. Subclinical disease activity (i.e. where sarcoidosis activity is             
present but below the threshold of clinical perception) (22), sleep disturbance (23), medication             
side-effects (24) and co-existent depression or anxiety symptoms (25) can all cause fatigue and are               
all 
potentially modifiable. The severity and impact of fatigue varies markedly between patients with             
similar disease burdens. 
 
No objective measures exist to quantify fatigue. Thus, fatigue severity is defined by patient              
perception, including limitation of activity. Monitoring change is equally dependent on patient            
reported change (significantly better/unchanged/significantly worse). Quantification of fatigue        
through formalised and validated questionnaire measurements (e.g. the Fatigue Assessment Scale) is            




generic breathlessness scales may be used when monitoring fatigue but again none have been              
specifically investigated for sarcoid fatigue (26, 27). 
 
Clinical Practice Points 
 
1. The respiratory examination in pulmonary sarcoidosis is often normal, and is an unreliable              
measure of disease extent or morbidity 
 
2. Pulmonary function tests are often normal in non-fibrotic sarcoidosis, and may not reflect disease               
activity or symptom burden 
 
3. 
Screening for extra-thoracic disease is important. At baseline, patients should have a full blood              
count, biochemical tests (including urea and electrolytes, liver function tests, calcium), serum ACE             
levels (non-unanimous consensus) and a 12-lead ECG.  
 
4. In patients with eye symptoms, a baseline ophthalmic review should be undertaken by either an                
optician or an ophthalmologist (depending on the severity of symptoms) 
 
5. Patients should be asked routinely about fatigue and mood disturbance 
 
6. A comprehensive exposure and occupational history should be taken to exclude both berylliosis              











Cardiac involvement in sarcoidosis represents a potentially dangerous form of the disease, especially             
when manifesting with life-threatening arrhythmias and impaired cardiac function. Cardiac          
manifestations may indeed be the initial method of patients presenting with newly diagnosed             
sarcoidosis. This section focuses on diagnostic challenges of cardiac sarcoidosis in the context of              
known pulmonary involvement. The management of cardiac sarcoidosis lies beyond the scope of this              
statement. If diagnosed, patients should be referred to a team with specialist expertise in cardiac               
sarcoidosis. 
 
The 1999 ATS/ERS sarcoidosis statement recommended screening of all patients presenting with            




sensation of a fluttering or fast heart beat which lasts from between a few seconds to several                 
minutes or longer, chest pain, pre-syncope/syncope) and ECG (28) but this approach has a low               
sensitivity (25%) and specificity (46%) (29) (30). ​This prompted the recommended addition of             
echocardiography (to look for cardiac dysfunction) in the presence of an abnormal ECG or a               
suspicion of cardiac sarcoidosis, as described by the 2014 Heart Rhythm Society (HRS) expert              
consensus statement ​(31). The use of the echocardiogram is both to look for cardiac sarcoidosis              
(albeit with low sensitivity) prior to a more advanced imaging modality and also to look for any other                  
cause of cardiac dysfunction which may be seen in sarcoidosis e.g. left ventricular heart disease or                
pulmonary hypertension. The HRS strategy captures clinically overt cardiac disease (conduction           
abnormalities, ventricular arrhythmias and new onset unexplained heart failure), present in 5-10% of             
the general sarcoidosis population (1), but misses sub-clinical cardiac disease, present in 20-30% of              
cases (29). Cardiac magnetic resonance imaging (CMR) is the diagnostic tool of choice for              
identification of cardiac sarcoidosis with a high diagnostic yield according to HRS criteria (sensitivity              
97% and specificity 100%, AUC: 0.984) (30). Cardiac PET scanning also benefits from high sensitivity               





Multidisciplinary discussion is currently recommended in the diagnosis of cardiac sarcoidosis (31)            
(32). Endomyocardial biopsy has a low yield and is seldom performed (33). Both advanced imaging               
modalities (CMR and PET) have considerable added value in diagnosis and prognostic evaluation but              
the radiation dose associated with PET should be considered if both imaging modalities are available.               
It is also important to note that specific patient preparation is needed for fluorodeoxyglucose              
(FDG)-positron emission tomography (PET) in such patients to suppress normal physiological uptake            
of glucose in the myocardium for image optimisation (34) (35) (36) (37). Diagnosis is based on a                 
combination of integrating ECG/Holter (advanced atrioventricular block, ventricular tachycardia) and          
echocardiographic abnormalities (left ventricular systolic or diastolic impairment) with abnormal          
features on advanced imaging (late gadolinium enhancement on CMR and significant FDG uptake on              
cardiac PET). Coronary artery disease needs to be carefully excluded as does other causes of cardiac                
inflammation e.g. myocarditis. Coronary artery disease should be considered in patients who have             
sarcoidosis and cardiac symptoms or left ventricular impairment, as patients with sarcoidosis may be              





The selective use of CMR in patients with pulmonary sarcoidosis, based on symptomatic screening,              
as recommended in the ATS/ERS and HRS statements, is confounded by the presence of exertional               
dyspnoea due to pulmonary disease. Breathlessness can be multifactorial in pulmonary sarcoidosis.            
Patients with disproportionate breathlessness (i.e. not explained by pulmonary function test           
impairment) or loss of exercise tolerance (out of keeping with the severity of pulmonary disease and                
not explained by other factors such as fatigue, elevated BMI and loss of fitness) should undergo                
CMR, with a 24-/48- hour Holter if there are persistent palpitations. In patients with infrequent but                
concerning palpitations, the use of an implantable loop recorder should be considered. Given the              
high prevalence of subclinical cardiac disease (29), the need for a low threshold for CMR is                
emphasised, if symptoms are suggestive.  
 
However, routine CMR screening in the general sarcoidosis population has not been validated and              
this applies equally to PET (performed under a specific cardiac protocol), which may be used in                
selected patients to identify cardiac inflammation. The value of detecting limited subclinical cardiac             
involvement is uncertain, with no current evidence of adverse events during follow-up (39), but no               





Pulmonary hypertension [PH] 
 
Sarcoidosis-related pulmonary hypertension (PH) is a significant contributor to sarcoidosis morbidity           
and mortality. In a recent large study, PH was confirmed by right heart catheterization in 29 of 452                  
patients with pulmonary sarcoidosis (6.4%) and was a major predictor of mortality, independent of              
age and extent of fibrosis on HRCT (40). The five-year survival was 55% in 126 patients with PH (41)                   
(42).  
 
The prevalence of PH is critically dependent on population selection. In unselected patients             
attending the outpatient clinic, a prevalence of approximately 6% has been reported, (40) (43),              
increasing to 47% in patients with exertional dyspnoea disproportionate to pulmonary function            
tests, and to 74% in patients listed for lung transplantation (44, 45). PH tends to present with                 
non-specific symptoms including shortness of breath, fatigue, weakness, angina and syncope.  
 
Echocardiogram remains the most appropriate initial, non-invasive screening tool for PH. ESC/ERS            




suspected PH and the presence of additional echocardiographic abnormalities should be used to             
make a decision about the need for right heart catheterisation (46). However, echocardiographic             
variables are often discordant with right heart catheter measurements of pulmonary artery            
pressure, especially in patients with concomitant parenchymal lung disease [with one meta-analysis            
documenting echocardiography sensitivity of 83% and specificity of 72% for pulmonary hypertension            
(47)]. Therefore, referral to a PH specialist (or initial referral to a local cardiac centre with expertise                 
in right heart catheterisation) may be warranted if indications other than echocardiographic            
variables (e.g. clinical features of right ventricular failure or specific ECG abnormalities) are             
suggestive of PH. Unlike other forms of ILD (e.g. idiopathic pulmonary fibrosis), the use of specific                
treatments for PH may be indicated in patients with sarcoidosis.  
 
Findings associated with PH include a severe reduction in DLco (Diffusing capacity for carbon              
monoxide) in the setting of a restrictive ventilatory defect, especially when disproportionate to lung              
volume reduction (46), an increase in the pulmonary artery diameter (​⩾​29 mm) and pulmonary              




desaturation (<90%) during 6-minute walk test (21), and the need for long-term oxygen treatment              
(42). 
 
PH more commonly represents a complication of pulmonary fibrosis than an isolated granulomatous             
vasculopathy (48). However, the confident identification of “disproportionate PH” in the setting of             
chronic lung disease is notoriously difficult. Therefore, based on diagnostic, prognostic and            
management considerations, there should be a low threshold for referral to a PH specialist.  
 
Clinical Practice Points 
 
 
1. Cardiac sarcoidosis and/or pulmonary hypertension should be considered in all patients with             
pulmonary sarcoidosis who have levels of breathlessness which are disproportionate to their lung             
function impairment. 
 
2. Baseline testing in all patients with suspected cardiac sarcoidosis (i.e. those with ECG 
abnormalities, cardiac symptoms or breathlessness out of context with their pulmonary function) 
should include an ECG and echocardiogram. ​Abnormalities in ECG or ECHO which suggest cardiac 






3. All patients with palpitations should be offered a 24 hour Holter monitor. 
 
4. In patients with pulmonary sarcoidosis, the presence of cardiac involvement, based on advanced              
imaging (cardiac MRI or PET) findings, should be confirmed by a multidisciplinary team with              
experience in both sarcoidosis and other forms of cardiac disease. There is a current initiative to                









Imaging is central to both the diagnosis and monitoring of pulmonary sarcoidosis patients. Typical              
chest radiograph findings may be highly suggestive of the diagnosis in appropriate clinical settings              
(Table 1) but a careful occupational history should be taken to exclude berylliosis and silicosis which                
can have similar CT appearances. However, thin section computed tomography (CT) is increasingly             
utilised to characterise subtle or non-specific findings or when there is diagnostic uncertainty. FDG              
PET-CT has been proposed to assess disease activity and distribution, and to monitor therapeutic              
response in complex cases. 
 
On chest radiograph, acute sarcoidosis is typically characterised by bilateral symmetrical hilar and             
mediastinal lymphadenopathy. Classical parenchymal changes include mid and upper zone          
predominant nodular or reticulonodular opacity and upper zone predominant fibrosis. However, the            




(Figure 2) but is limited by inter-observer agreement. Surveillance chest radiography in evolving             
cases every 3-6 months is typically used for patient monitoring given its low radiation dose. 
 




Scadding stage Findings % at presentation % with clinical and    
radiographic 
resolution untreated  
(49) 
0 Normal 5-15 n/a 
I Enlarged nodes only 45-65 50-90 
II Enlarged nodes and   
parenchymal changes 
30-40 30-70 
III Parenchymal changes without   




CT is more sensitive than chest radiography in characterising lymphadenopathy, particularly nodal            
calcification, and in detecting and characterising lung parenchymal features. Thus, CT is especially             
helpful in diagnosis when there is clinico-radiological discordance or when radiographic features are             
atypical. The presence of typical CT features (Figure 3) may prevent the need for invasive sampling                
(Table 2). However, a range of atypical CT features of sarcoidosis have led to its description as “the                  
great pretender​” (50). CT is more discriminatory than chest radiography in identifying pulmonary             
fibrosis, and may provide prognostic information (51) and help to guide therapeutic escalation or              
rationalisation depending on clinical scenarios. CT scans can also guide both endobronchial            
ultrasound-guided nodal sampling and transbronchial biopsy where required. Most sarcoidosis          
patients with clinically overt interstitial lung involvement will need a CT scan. However, it can be                
argued that in patients with typical clinical and chest radiographic features, CT is not required               




IV Fibrosis 5 0 
 
Surveillance CT should be limited to patients with unexplained deterioration in symptoms or lung              
function, those with “red flags” such as haemoptysis or pulmonary hypertension or when specific              









Typical CT features 
Chest site Feature 
Lymph node enlargement Hilar +/- mediastinal 
Bilateral, symmetrical 
Well defined homogeneous 
Lymph node calcification ‘Icing sugar’ 
‘egg shell’ 
Nodules Well defined 2-5mm 
Paraseptal predominance 
Fissural beading / peribronchovascular nodularity 
Coalescence – larger nodules / perihilar      
consolidation 





Volume loss / Architectural distortion 
Traction bronchiectasis 
Peribronchovascular  
Air trapping / Mosaic pattern  
Atypical CT features 
Chest site Feature 
Lymph node enlargement Unilateral / asymmetric 
Confluent consolidation / Ground glass     
opacity 
‘Alveolar sarcoid’ 
Solitary / multiple discrete nodules  
Miliary nodularity  
Bullae / cysts / aspergilloma Upper zone predominant 














Typical Clinical Presentation Non-Typical clinical 
presentation 
BHL on CXR with erythema 
nodosum and arthritis 
 
Confident clinical diagnosis HRCT and MDT discussion 
Typical CT findings  Confident clinical diagnosis MDT discussion - Consider 
biopsy or close observation 
Atypical CT findings MDT discussion - Consider 




CXR= Chest radiograph (x-ray) 
HRCT= High resolution CT (computerised tomography) scan 
MDT= Multidisciplinary meeting 
 
FDG PET is a sensitive means of detecting sarcoidosis inflammation (52). The Royal College of               
Radiologists 2016 PET-CT guidelines indicate that PET CT can be used in the assessment of               
sarcoidosis disease activity in highly selected cases when there is diagnostic uncertainty using             
conventional imaging, particularly where cardiac sarcoidosis is suspected (53).  
 
Bronchoscopy and biopsy 
An ​absolute diagnosis of sarcoidosis requires a tissue biopsy. However, there are two scenarios in               
which one is not needed to make a ​confident ​diagnosis (Figure 4). 
 
- In patients with Lofgren’s syndrome and no overt alternative diagnosis, close monitoring is             





- In patients with long-standing pulmonary disease following a typical clinical presentation and            
stable typical imaging findings, an alternative diagnosis is highly unlikely. In such cases an              
MDT discussion of the clinical case may be needed in order to make the diagnosis with                
confidence. 
 
These two scenarios aside, the diagnosis of sarcoidosis should not routinely be made on clinical               
grounds alone, particularly if pharmacological treatment is needed or if there is diagnostic             
uncertainty, i.e. a need to exclude a) lymphoma, tuberculosis or carcinoma where there are enlarged               
lymph nodes; or b) other forms of interstitial lung disease (ILD). Tissue should be obtained from the                 
most accessible site, for example a skin lesion or peripheral lymph node if abnormal findings are                
present. If no peripheral site is present then intrathoracic sampling is indicated via fibreoptic              
bronchoscopy. It is essential that the patient be involved in this decision-making process.             
Bronchoscopy carries a specific morbidity risk and this should be clearly explained to patients. Some               
patients may opt for careful follow up without an immediate biopsy, with biopsy undertaken at a                





Endobronchial appearance at bronchoscopy is normal in up to two thirds of patients with sarcoidosis               
(55). Nodules, classically 2-3mm waxy yellow mucosal lesions with a mucosal cobblestone            
appearance, should be biopsied at bronchoscopy (56, 57). Bronchoalveolar lavage (BAL) is a useful              
diagnostic adjunct: an elevated BAL lymphocyte count of 15-25% provides support for            
granulomatous disease (including sarcoidosis but also seen in accelerated silicosis) whereas a count             
>50% is more suggestive of hypersensitivity pneumonitis or cellular non-specific interstitial           
pneumonia. However an accurate cell differential count may not be possible in all hospital              
pathology departments (58). A CD4:CD8 ratio >4 in the absence of an increased proportion of other                
inflammatory cell types is highly specific (>95%) for sarcoidosis when compared with other             
inflammatory ILDs (12, 59, 60). The BAL should be performed in a ‘high volume’ manner i.e.                
installation of 100 to 300mls into a distal airspace as per ATS guidance for ILD bronchoscopy (12) and                  
then samples sent for a cell differential count (local expertise permitting) and microscopy and              
culture (including an examination for acid fast bacilli) to rule out infection as an alternative diagnosis                
or complication. There is no validated role for repeated BAL in disease monitoring (61). 
 




normal although this yield may be lower (55) and in transbronchial biopsy (TBBx) has been reported                
as 40-90% with a pneumothorax rate of 1-9% in diffuse ILD (62). Whilst the current BTS advice                 
remains to perform TBBx under fluoroscopy guidance (63), there is no evidence that this either               
reduces the rate of pneumothorax or increases diagnostic yield in diffuse lung diseases (63-67). 
 
Endobronchial ultrasound (EBUS)-guided transbronchial node aspiration (EBUS-TBNA) with the         
addition of EUS-TBNA (endoscopic ultrasound-TBNA) has revolutionised the diagnosis of nodal           
disease over and above the use of conventional TBNA (68-71). The diagnostic yield in sarcoidosis in                
meta-analyses ranged from 54% to 93% with a pooled sensitivity of 79%. The varied yields are likely                 
to be explained by variability in the staging, number of samples taken and the variable use of ROSE                  
(rapid onsite ‘pathologic’ examination) (72, 73). Until recently, the utility of EBUS-TBNA in             
sarcoidosis continued to be debated (74, 75). However, the GRANULOMA trial showed that in stage               
I/II disease, the EBUS-TBNA yield was 74% compared to 48% with EBB/TBBx (p<0.01) (76). A               
subsequent randomised controlled trial revealed that EBUS-TBNA had the highest diagnostic yield            
(74.5%), which was improved over cTBNA (48.4%, P = 0.004) or EBB (36.3%, P < 0.0001). The addition                  




against the increased time and risk needed for the procedure (77). Based on current evidence, an                
EBUS-TBNA is an appropriate primary diagnostic approach for stage I and II sarcoidosis, variably              
combined with EBB, TBBx and BAL (78) as detailed in figure 4.  
Cryobiopsy, a recently developed technique which can be performed on self-ventilating patients            
under deep sedation, allows the retrieval of significantly larger samples without the crush artefact              
seen in TBBx (79-81). Safety concerns include pneumothorax and the potential for significant             
bleeding, especially in less experienced hands. The added value of cryobiopsy over EBUS-TBNA +-              
TBBx in the diagnosis of sarcoidosis is unclear, particularly when weighing up the balance of yield                
and procedural risk. 
 
 
If conventional bronchoscopic biopsies are non-diagnostic, the clinician (or MDT) must decide how             
far to pursue a tissue diagnosis. For example, a patient with a non-diagnostic EBUS-TBNA and               
diagnostic uncertainty may be invited to undergo mediastinoscopy, or a TBBx (if sufficient             




EBUS-TBNA (with sufficient tissue to ‘rule out’ lymphoma and carcinoma) a clinical diagnosis of              
sarcoidosis might be made. It is essential that the wishes of the fully informed patient be taken into                  
account in this decision-making process. 
 
Clinical Practice Points 
 
 
1. All patients with suspected sarcoidosis should have a CXR. If they have typical findings on a                 
radiograph with a typical clinical presentation (eg in the context of Lofgren’s disease) then a CT scan                 
may not be necessary as long as patients are followed up in clinic with a repeat CXR within 3 months                    
and a CT scan performed if circumstances change. 
 
2. Multi-disciplinary review of chest imaging is recommended for all patients with a non-typical              
clinical presentation or CT appearance to determine the need for a confirmatory bronchoscopy or              
biopsy. 
 
3. When performing a bronchoscopy, patients with predominantly lymph node disease should            
undergo an EBUS whereas those with predominantly parenchymal disease should have           
transbronchial biopsies. If both nodal and parenchymal disease is present, EBUS is the preferred              





4. All patients should be part of the decision making process when deciding on whether a biopsy is                  
necessary or whether it is safe to follow them up in the clinic alone, with a view to revisiting the                    








Overview of outcomes and broad indications for treatment 
 
Sarcoidosis is widely viewed as a benign disease, based on good outcomes in the majority of                
patients, with regression or stabilisation of pulmonary disease. However, in recent cohorts of             
sarcoidosis patients, sarcoidosis itself has been the single most frequent cause of death, with              
mortality clearly exceeding that in matched general populations (82) (42) (83). In one cohort, the               
need to introduce sarcoidosis-specific therapy within three months of diagnosis was a marker for a               
major increase in mortality (HR 2.34 [95%CI 1.99-2.75]) (82). Overall, in 6-8% of patients with               




and/or pulmonary hypertension) causes up to 70% of sarcoidosis-attributable fatalities with cardiac            
involvement accounting for most remaining deaths (84).  
 
However, these data may seriously understate mortality linked to sarcoidosis as fatal comorbidities             
due to sarcoidosis treatment are not considered . Comorbidities found with sarcoidosis include             
coronary artery disease, stroke or transient ischaemic attacks, arthritis, depression, diabetes,           
hypertension and major osteoporotic fractures, all of which are associated with increased            
hospitalization (38) (85) (86) (87) (88). Their effect on quality of life and mortality is well                
documented, with linkages between fatal outcomes and both the number of comorbidities and a              
comorbidity burden score in sarcoidosis (87) (88). Steroid usage in sarcoidosis was a strong              
determinant of a high composite comorbidity score (that included diabetes, hypertension, weight            
gain, hyperlipidaemia and osteoporosis) (86). It is also likely that a proportion of infective deaths in                
treated patients are directly due to steroid or immunosuppressive treatment. 
 
Significant pulmonary, hepatic and renal disease are readily identified by recommended screening            




clinically overt. It has been estimated that approximately 30% of patients with sarcoidosis have              
clinically significant major organ involvement (89). Long term mortality due to sarcoidosis            
approximates 20-25% (i.e. 6-8%/30%) when there is overt major organ involvement. This proportion             
increases when treatment-related mortality is taken into account (84). 
 
Given the need to minimise treatment-related comorbidities in sarcoidosis, we recommend that            
treatment should be initiated ​only if there is a) ​potential danger of a fatal outcome or permanent                 
disability​; or b) ​unacceptable loss of quality of life​. The approach to treatment differs according to                
the 
indication. Historically, most recommended regimens have consisted of initial high dose steroid            
therapy, followed by a prolonged consolidative approach (e.g. Prednisolone 10-20mg daily).           
However, higher dose regimens, needed in patients at risk of death or permanent disability, are               
often counterproductive when treatment is introduced for quality of life reasons. Unfortunately,            
side-effects are sometimes more debilitating than the symptoms for which treatment has been             
introduced, with a net reduction in quality of life. 
 





The accurate introduction of therapy requires careful risk stratification, with the identification of             
patients with advanced disease (​dangerous sarcoidosis​) and also patients at higher risk of             
progression to advanced disease (​potentially dangerous sarcoidosis​). Advanced pulmonary disease is           
associated with a major increase in mortality despite treatment (51) (40) (90). Therefore, treatment              
should be introduced earlier in the course of disease to pre-empt this situation. Indications for               
treatment in pulmonary disease, based on disease severity, are discussed in detail below. 
 
The treatment of sarcoidosis-related morbidity 
 
With the exclusion of dangerous/potentially dangerous disease, the introduction of treatment for            
loss of quality of life is critically dependent on the values and choices of the patient and must take                   
into consideration their wishes. The patient is the only person with a true perception of the impact                 
of sarcoidosis symptoms on their daily life. Loss of quality of life results from a “package” of                 
symptoms, which varies widely between patients. Importantly, pulmonary sarcoidosis is often           




the single most frequent source of unacceptable loss of quality of life (91) and is addressed in detail                  
later in this statement.  
 
It is important that whilst initial investigations to screen for dangerous/potentially dangerous            
disease are undertaken, the patient is asked to consider carefully whether the impact of sarcoidosis               
on daily life is sufficiently debilitating to cause them to choose to be treated. It must be stressed                  
that accurate management is not dependent solely on medical expertise but requires the             
empowerment of patients in decision-making. In essence, this is a risk-benefit discussion, with the              
decision made by the patient informed by expert knowledge of potential benefits and treatment              
side-effects.  
 
Historical high-dose treatment regimens geared to dangerous/potentially dangerous sarcoidosis are          
unsuited to treatment aimed at improving morbidity. The choice and dose of agent should be               
negotiated with the patient with the understanding that the patient should have the freedom to               
cautiously modify the starting regimen, within its therapeutic range, by titration against symptoms             




different patients, with the possible introduction of low dose steroids at variable doses,             
hydroxychloroquine or, even, a second-line agent such as methotrexate, either alone or in             
combination. The patient​, ​as the sole judge of the impact of morbidity, should be given the                
opportunity to take the lead in treatment decisions, in contrast to the treatment of              
dangerous/potentially dangerous disease. However, it must also be expected that some patients            
will opt to be wholly guided by medical advice. 
 
The desire to empower the patient must be balanced against the obligation of the treating physician                
to 
consider potential medication toxicities, and therefore a truly informed discussion should be            
undertaken. This allows on the one hand patient concerns about steroid therapy to be addressed,               
with critical differences between low and high dose steroid regimen explained, and if necessary, the               
use of alternative agents from the outset. On the other, it provides meaningful context for a “slow                 
hand” approach, in cases in which the clinical presentation may not justify the risk of potentially                







The first treatment decision is whether or not to introduce immunosuppressive drugs (ie those              
which suppress the immune system). This is influenced by the presence of significant pulmonary              
dysfunction, unacceptable loss of quality of life and the views of the patient. This statement focuses                
on the treatment of aggressive or persistent pulmonary disease. In reality, many patients with major               
pulmonary disease also have other organ involvement and/or debilitating symptoms and require            
careful nuancing of therapy on a case by case basis. 
 
Disease-modifying drugs can be divided into three sections: a) steroids (e.g. Prednisolone), b)             
classical immunosuppressants (most commonly Methotrexate, Azathioprine, Leflunomide and        
Mycophenolate) and c) biologics (e.g. Infliximab). Usual international practice, based on biological            
rationale and accumulated clinical experience, has been to initiate treatment with Prednisolone. It             
should be acknowledged that this has never been definitively validated by controlled data. Despite a               
multiplicity of reports, steroid therapy has never been evaluated according to specific treatment             
indication (severe pulmonary disease as opposed to impaired quality of life). Many studies include              




no symptom burden. With these caveats, the current statement accords with the existing expert              
consensus. It is stressed that this decision should be multidisciplinary with the integration of all the                
tabulated variables. 
Steroid regimens  
 
The use of exact pulmonary function test thresholds is made difficult by individual variations and               
baselines. For example, the use of a pulmonary function test threshold (e.g. Dlco<60% of predicted)               
is made more difficult by the normal pre-morbid range of 80-120% of predicted – thus, a value of                  
60% in an individual patient may indicate a real reduction to anywhere between 25% and 50% of the                  
pre-morbid value. Given this constraint, treatment should be ​considered when there is significant             
reduction in pulmonary function tests e.g. Dlco<65%, spirometric volumes <70% or if there is a 10%                
drop from baseline FVC or 15% drop from baseline Dlco. The caveat is presence of inactive fibrotic                 
disease which may have resulted in irreversible but non-progressive lung function loss. In some              
cases, patients with progressive breathlessness due to pulmonary disease (with the careful exclusion             
of other causes of breathlessness e.g. cardiac disease) may be suitable for steroid initiation despite               




individual basis with clear discussion between the clinician and the patient. Good control of disease               
is shown by regression of disease or lack of progression, as judged by symptoms, radiologic imaging                
and pulmonary function variables.  
 
The exact dose of prednisolone depends upon the clinical setting. When disease is long-standing              
and insidiously progressive, lower dose protective therapy from the outset may be appropriate (e.g.              
Prednisolone 10mg daily). Aggressive therapy with intravenous methylprednisolone is seldom          
warranted in pulmonary disease in isolation but may be required with rapidly progressive             
extra-pulmonary disease (e.g. cardiac sarcoidosis, neurosarcoidosis, severe optic neuritis). 
 
In many cases, the decision to treat is a fine line and needs to be negotiated with the patient where                    
patient views often determine the immediate approach. If treatment is withheld, it is helpful to               






In the absence of life-threatening disease, initial treatment comprises 20–40 mg/day Prednisolone            
for 4-6 weeks, followed by slow tapering (e.g. reducing by 5mg every 2 weeks) to a maintenance                 
dose, usually between 5-10mg/d. ​The aim is to bring disease under control and to maintain this                
control until the threat to the organ is resolved.  
 
Subsequent treatment is critically dependent upon the initial response. If there is major regression              
of disease, or residual disease is only moderately severe, a rapid reduction to low dose steroid                
therapy can be justified. However, a lengthy maintenance period is often required. Some patients              
have persistent, severe chronic disease: under-treatment in this context risks further irreversible            
disease progression, yet a preventative effect of treatment has not been definitely established. The              
BTS study of Gibson and colleagues suggests that approximately 40% of patients will spontaneously              
remit within the first 6 months, but it is not clear which individual patients will do this and which will                    
have progressive chronic disease (92). Adequate bone protection should be considered in all             





In the longer term, a target dose of 5-10 mg/day is broadly appropriate but ongoing side-effects such                 
as weight gain and osteoporosis may require individualisation of the dose. Continued treatment is              
indicated if withdrawal or dose reduction is associated with relapse (with a brief return to higher                
dose treatment and tapering to the previous dose if the relapse is major). Attempts at withdrawing                
Prednisolone should be made every 6-12 months. The potential development of major comorbidities             
due to steroid therapy should be kept constantly in mind. 
 
Löfgren syndrome occurs in up to 30% of patients and remits in 70%–80% within two years (93).                 
Although organs are seldom threatened (some patients can be managed with NSAIDs alone for              
arthralgias), systemic symptoms (especially severe arthralgia) often require steroid therapy.          
However, treatment is usually needed for less than three months, with higher doses (e.g.              
30-40mg/daily) for 1-2 weeks and tapering within weeks to months. Paradoxically there is a small               
sub-group of patients who may do worse with steroid treatments and these patients should be               





Analysis of the British Thoracic Society Sarcoidosis Registry showed that 8% of all patients with               
pulmonary sarcoidosis were prescribed inhaled steroids (94). Although an obstructive defect is            
present in almost a quarter of UK patients with sarcoidosis (95), there is no evidence for inhaler                 






Before second line agents are introduced, the diagnosis of sarcoidosis should be reviewed and              
compliance with therapy should be discussed in a sensitive manner. The need for second line agents                
will usually indicate referral to a specialist tertiary centre but clinicians in secondary care with a                
strong experience of their use will be well placed to initiate treatment and monitor these patients. 




a. progression of pulmonary disease or an unacceptable symptom burden despite adequate           
steroid therapy 
b. intolerable steroid side effects 
c. inability to taper steroid below 10 to 15 mg/day  (97) (98) (99) (100)  
d. The presence of major comorbidities likely to be adversely affected by steroid therapy             
(severe obesity, diabetes mellitus, osteoporosis, hypertension).  
e. A strong patient aversion to the use of steroids, in which case, a second line agent may                 
occasionally be used as initial therapy.  
Absence of consensus on the definition of disease phenotypes, treatment indications and validated             
outcome measures contributes to the paucity of evidence to support second line treatment             
recommendations (101) Options for escalation include methotrexate (used most frequently),          
mycophenolate, leflunomide and azathioprine. All of these agents carry a not insubstantial risk of              




implications for those planning conception. For these reasons, all immunosuppressive drugs need            
blood test monitoring and whilst this is usually defined in local centres, one acceptable regimen will                
be for full blood count, renal and liver blood monitoring every 2 weeks on initiation of drug and then                   
(if levels are normal and stable) a reduction in frequency after 2 months to monthly testing and then                  
a further reduction after 6 months to blood testing every 3 months (102). 
The side effect rate of these drugs are variable: methotrexate (18%), mycophenolate (21%),             
leflunomide (34%) and azathioprine (35%) (103) (104) (105). Prior to treatment with any of the               
following agents a full blood profile, renal function, liver function and viral hepatitis serology should               
be measured. Those with an eGFR of less than 30 or with an aminotransferase level above two times                  
the upper limit of normal (unless this is solely due to sarcoidosis itself), or chronic infection with                 
hepatitis B or C should not be candidates for these treatments.  
Methotrexate, is an antimetabolite drug and the most widely used agent second line agent for               
pulmonary sarcoidosis enabling a reduction or cessation of steroids, although it must be             




be justified as first choice second-line immunosuppression, with individual side-effect profiles on            
initial use often highly influential). In retrospective studies (which should be cautiously interpreted),             
methotrexate has had an efficacy of 50% and response rate of 40-60%, using FVC and DLCO as                 
outcome measures,  (106) (107) (108) (109) (110) (103).  
Methotrexate is administered orally, or subcutaneously in cases of refractory nausea or insufficient             
response at six months, is typically initiated at 5-10mg/week and incrementing fortnightly to a target               
of 15-20 mg per week as tolerated (110). Folic acid should be prescribed routinely (5 mg weekly) to                  
reduce the incidence of myelosuppression.  
Methotrexate-induced pneumonitis is rare in sarcoidosis but when it occurs it may be difficult to               
distinguish from progressive interstitial lung changes. A recent large randomised controlled trial of             
methotrexate in cardiac disease found that the incidence of acute pneumonitis was 0.2% (111). It is                
characterised by a non-productive cough, dyspnoea, and fever, which can occur acutely i.e. within              
days to weeks after initiation, or can occur insidiously. The development of new ground-glass on               




pre-existing imaging abnormalities. Poorly formed granulomas may be seen on lung biopsy although             
fibrosis is not a feature. Recovery usually occurs after withdrawal of the drug.  
Other significant complications include hepatic fibrosis (in up to 10 percent of cases when the               
cumulative dose exceeds 5g, roughly equivalent to two years therapy at standard doses),             
leukopenia, nausea, alopecia and skin rash (108).  
Azathioprine  affects RNA and DNA synthesis thereby inhibiting lymphocyte proliferation, a key           
feature of sarcoidosis immune pathology although the exact mechanism of action in sarcoidosis is              
not 
clear (109). There are no randomised trials of azathioprine in pulmonary sarcoidosis but open-label             
series and cohort study suggest a modest improvement (103). The usual starting dose             
of azathioprine is 50 mg per day, increased by 25 mg every two to three weeks until the                 
maintenance dose is reached, typically 2 mg/kg. The most common side effects include nausea,            
vomiting, diarrhoea, rash, fever and malaise. Pancytopenia, which can be difficult to distinguish from              
lymphopenia associated with sarcoidosis, abnormal liver function and an increased risk of            
subsequent malignancy have been reported. TPMT serum levels should be measured to ensure they              




methotrexate and azathioprine in a direct comparison except for a higher rate of infection with               
azathioprine (35 versus 18 percent), possibly reflecting the selective use of prophylactic antibiotics             
with methotrexate treatment (103). 
Mycophenolate mofetil (MMF), an inhibitor of lymphocyte proliferation and activity, is used to treat              
a variety of connective tissue disease-associated ILDs associated and is generally well tolerated             
(112). Data regarding the use of MMF in sarcoidosis are limited and it should not considered before                 
methotrexate or azathioprine unless there is a specific reason. However, one retrospective analysis             
in 
pulmonary sarcoidosis suggested that MMF may be of benefit in those who have failed an initial                
second line treatment and may, in addition, enable steroid reduction (105). Doses of 1-1.5g twice               
daily are typically used. Neutropenia is less of a problem with MMF than with other               
immunosuppressive agents, but may occur. Nausea and diarrhoea may be dose limiting and it has               
potential teratogenicity in women of child bearing age, as do other second line agents.(113). 
Leflunomide, an antimetabolite similar to methotrexate but with less gastrointestinal toxicity, may           




arthritis, but small case series data suggest a beneficial effect on FVC and steroid reduction with                
leflunomide (104) (105) (114) (115). The most common adverse effects of leflunomide are nausea,             
diarrhoea, abdominal pain, hypertension, hepatotoxicity, rash, and peripheral neuropathy. 
Cyclophosphamide is an alkylating agent that is metabolised by the cytochrome P-450 system into             
active metabolites which decrease lymphocyte numbers and function and may also have            
anti-inflammatory effects. Despite being overall one of the most commonly used           
immunosuppressive agents, it is rarely used as a steroid-sparing agent in the treatment of              
sarcoidosis due to its toxicity profile.  
Hydroxychloroquine is advocated primarily for use in fatigue, joint and skin sarcoidosis but it may be                
used as an adjunct when helping patients wean off higher doses of prednisolone. The usual dose is                 
200mg once or twice a day. Retinal and cardiac toxicities are rare but potentially serious. An                
ophthalmic examination is recommended at the time of treatment initiation (or within 12 months of               




Patients should then be referred for annual review after five years of treatment (116). Patients               
should also have a baseline ECG to exclude long QT interval. 
All patients on long term immunosuppression should be counselled against the risk of repeated              
infections. If this occurs, patients may need prophylactic antibiotics (including against PJP). All forms              
of immunosuppression should also be reviewed for their potential for drug interactions with existing              
medications and additionally dose reductions may need to be used if patients have liver or renal                
disease. 
Biological agents and antifibrotics 
Biological agents are considered third line therapeutic agents, to be initiated in pulmonary disease              
only after a failure of second line treatment. In the UK, these are not routinely available and can only                   
be prescribed through specialist tertiary centres. 
Tumour necrosis factor (TNF) is a pro-inflammatory cytokine thought to accelerate the inflammatory             
process in sarcoidosis via its role in maintenance of granuloma formation. Thus, using agents that               




with CD4​+ ​lymphopenia (117). Infliximab given in combination with methotrexate or azathioprine            
appears to improve disease control (118) (119) (117). The major adverse effects include increased              
susceptibility to infection, particularly mycobacterial and invasive fungal infections,         
infusion-reactions, alopecia, oral candidiasis, visual field defect and increased rate of fatal pulmonary             
embolism. Paradoxically, the development of non-caseating granulomata consistent with sarcoidosis          
has been reported during anti-TNF therapy for other diseases (120). Patients should be screened for               
latent TB infection (including the use of Interferon Gamma Release Assay testing) prior to starting               
anti-TNF agents (121). If latent TB is detected, patients should have anti-TB treatment as per local                
guidelines for treatment of latent TB infection prior to starting biologic therapy. Infliximab is given               
initially every 2 weeks and then every 4-8 weeks as part of maintenance therapy. 
The antifibrotic medications pirfenidone and nintedanib are currently only available in the United             
Kingdom for Idiopathic Pulmonary Fibrosis (IPF) (122, 123). However, the recent INBUILD study             
reviewed patients with non-IPF fibrotic lung disease including NSIP (Nonspecific interstitial           
pneumoinia), hypersensitivity pneumonitis and sarcoidosis. Although the numbers of sarcoidosis          




patients treated with nintedanib vs controls, paving the way for the use of antifibrotics in               
progressive fibrotic lung diseases including sarcoidosis, once other immunosuppressive therapies          
have been exhausted (124). 
 
Lung transplantation 
In those with advanced pulmonary fibrosis and/or associated pulmonary hypertension, lung           
transplantation may be considered. The indications for lung transplantation in sarcoidosis are            
outside the scope of this statement but one approach would be to follow that similar to indications                 
for Idiopathic Pulmonary Fibrosis i.e. a significant acute (e.g. 10% over 6 months) drop in FVC or                 
DLCO in association with respiratory failure (125). Bilateral lung transplantation appears to be             
associated with slightly better survival than single lung transplantation (126) (45) (127). Following             
lung transplantation, asymptomatic foci of non-caseating granulomas suggestive of recurrent          
disease have been identified in the allografts of sarcoidosis patients, but clinically significant organ              





Management of fatigue 
 
When managing a patient with sarcoidosis-associated fatigue, alternative causes should be excluded            
(figure 5). Anaemia, vitamin D deficiency, iron deficiency, thyroid dysfunction or hypercalcaemia may             
all contribute to symptoms but as described earlier careful consideration should be given to vitamin               
D supplementation and monitoring to prevent toxicity. Screening for sleep disorders, including            
obstructive sleep apnoea, insomnia and periodic limb movements, should be undertaken if            
symptoms suggestive of these conditions are present. Sleep disorders may develop due to             
steroid-induced weight gain. Depression and anxiety may co-exist and exacerbate fatigue severity.            
Patients with sarcoidosis and fatigue may also display skeletal muscle weakness (129). Multiple             
aetiologies may therefore co-exist in an individual patient.  
 
If no reversible non-sarcoidosis cause can be identified, strategies for directly managing or reducing              
fatigue should be initiated if there is unacceptable loss of quality of life. A short trial of steroid                  
therapy may be helpful (non-unanimous consensus) in order to identify the minority of patients in               




impact on their daily lives; and b) the judgment by the treating physician that this intervention is not                  
outweighed by potential harm, taking into account comorbidities such as osteoporosis, high BMI,             
diabetes and hypertension.  
 
There was no group consensus on whether a treatment trial should consist only of low dose steroid                 
therapy (e.g. Prednisolone 5-10mg daily) or an initial challenge with higher dose treatment. When              
fatigue is steroid responsive, low dose maintenance therapy (e.g. prednisolone 5-10mg daily) may be              
appropriate with the exact dose determined by titration by patients against symptoms.            
Hydroxychloroquine in combination with steroids may be beneficial but this is anecdotal at best              
(130).  
 
Ginkgo Biloba has been promoted as a natural remedy for fatigue. It is widely available and is well                  
tolerated aside from an increased risk with concurrent anticoagulation (131-133), although evidence            
for efficacy is poor and it has not been trialled in patients with sarcoidosis. In refractory fatigue                 
neurostimulants can be used for symptomatic relief but these are currently used off-licence.             




both appear to be beneficial for fatigue and were well tolerated over a short period but are used off                   
licence and should be used in caution in patients with psychiatric diseases including depression.              
(134, 135). 
 
Non-pharmacological management strategies and therapies may complement pharmacological        
interventions. Fatigue diaries and pacing techniques enable patients to identify the severity and             
variability of their fatigue, and to structure activity within their physical and mental capabilities.              
Structured exercise routines, similar to pulmonary rehabilitation, have shown evidence of benefit in             
some patient groups and patients with progressive pulmonary sarcoidosis may be suitable for             
standardised pulmonary rehabilitation programmes (136), but this may not be suitable for all. Advice              
on exercise therapy from physiotherapists as part of the multidisciplinary team may be helpful in               
some cases. Mindfulness techniques have also been shown in one small study to be helpful in                
sarcoid fatigue (137). 
 
It is likely that a combination of the suggested options may be required, with an individual strategy                 




and make a joint decision on the management plan, included goals of therapy, with regular planned                




Clinical Practice Points 
 
1. There is often a fine line to making the decision to start pharmacological treatment and all                 
patients should be fully informed and be at the heart of this decision making process. 
 
2. 
Whilst there is no good evidence for any drug regimen in sarcoidosis, the majority of patients                
needing treatment should initially be treated with steroids ranging from 10mg prednisolone per day              
in long-standing and insidiously progressive disease, up to 20-40mg per day in more acute disease. A                
maintenance dose of 5-10 mg after these initial doses for 6-12 months is usual. 
 
3. Most patients who need treatment should be offered methotrexate (administered orally, or             
subcutaneously) as the first choice of second line agent. 
 
4. Referral for lung transplantation should be considered in all patients with advanced pulmonary              





5. All patients with sarcoidosis related fatigue should have a systematic approach to diagnosis of the                
cause of fatigue and management initiated as appropriate. 
 
6. In line with other chronic lung conditions, patients should be offered smoking cessation advice               
and support for anxiety or depression if needed. 
 
6. Monitoring, discharge and withdrawal of treatment 
 
Role of monitoring 
Patients with sarcoidosis should be monitored to a) observe spontaneous resolution in recently             
diagnosed cases, b) look for progression or confirm improvement or stability in untreated patients,              
c) determine the effect of anti-inflammatory treatment and d) look for relapse in patients who are                
tapering or have discontinued therapy. A realistic outcome target should be decided jointly by the               
clinician and patient at the outset, and may include resolution, improvement, or stability, with or               






Symptoms and their impact on quality of life should be assessed at every visit, with reference to                 
pre-defined individualised goals. In steroid-treated patients, changes in symptoms are the prime            
guide to escalation or withdrawal of treatment. Assessment may be complicated by adverse effects              
of steroid therapy which overlap with features of sarcoidosis, such as fatigue and sleep disturbance.               
Similarly, intercurrent illness such as respiratory infection can contribute to symptoms. Therefore, if             
disease progression is suspected corroboration is required, initially with chest X-ray and pulmonary             
function testing. Consideration should be given to cardiac sarcoidosis, pulmonary embolism (138) or             
pulmonary hypertension if breathlessness is worsening.  
 
Lung function tests 
Lung function tests are used to monitor changes in airflow obstruction, pulmonary restriction, or low               
gas transfer. There are no thresholds that define a significant change in lung function in sarcoidosis,                




not due to measurement variability. In sarcoidosis these thresholds should not be used in isolation               
but should be integrated with symptomatic and with possible imaging changes.  
Disproportionate serial reduction in FEV1 may denote increasing airflow obstruction due to            
bronchial involvement (139, 140) despite stable chest X-ray appearances. The FVC is sensitive to              
changes in disease severity in patients with ILD, and is usually concordant with changes in DLco, and                 
may function as a similar marker of disease progression in sarcoidosis specifically (141). A falling               
DLco associated with stable spirometry should raise the suspicion of pulmonary hypertension. 
 
Chest radiographs 
Increasing lung opacities seen on chest X-ray are seen in many (but not all) patients with worsening                 
pulmonary sarcoidosis, and chest X-ray deterioration correlates with worsening symptoms and           
declining lung function (142). However, a change in Scadding X-ray stage is uncommon and is an                
insensitive marker of change (143). In patients withdrawing from steroid therapy, chest X-ray             






Serial CT imaging should not be performed routinely but repeat CT can be valuable for assessing                
suspected disease progression when there is discordance between symptoms, chest X-ray, and            
physiology. Review of chest imaging in a multi-disciplinary format is recommended. The focus should              
be on assessing changes in the lung parenchyma which indicate disease progression (145). Lymph              
node enlargement in isolation is not a marker of progression. CT scoring systems (146) are of                




Serum ACE and other disease activity markers 
Measures of granulomatous inflammatory ‘activity’ in sarcoidosis including serum ACE activity, BAL            
lymphocytes, and ​67​Gallium scanning correlate poorly with disease progression and have little value             
in monitoring sarcoidosis (non-unanimous consensus) or predicting treatment response (147). Even           
in apparently self-resolving disease, serum ACE activity may remain elevated but this is not a cause                
for concern. Markers of disease activity are often suppressed with anti-inflammatory therapy and do              





Other blood tests 
Because of the risk of hypercalcaemia, serum calcium should be monitored, particularly in summer              
months when production of cholecalciferol is highest due to skin exposure to UVB light. Serum liver                
function tests are useful for monitoring patients with hepatic sarcoidosis, but it is unusual for               
clinically significant liver disease to arise ​de novo ​in patients with normal liver function tests early in                 
the disease course. 
Extra-pulmonary sarcoidosis 
When significant extra-pulmonary disease is present involvement of the relevant specialists and            
multidisciplinary discussions for decision making are recommended. 
 




A trial of withdrawal of steroid therapy is typically performed after 6-12 months in patients with                
controlled disease. Monitoring of treatment tapering and withdrawal focusses on detecting           
worsening disease, which must be distinguished from adrenal insufficiency or steroid withdrawal            
syndrome.  
 
Risk of relapse is higher in patients who have received steroid therapy than in treatment-naïve               
patients, with reported relapse rates of 13-75% when anti-inflammatory treatment is withdrawn            
(142). Importantly, most relapses occur within 1 year of discontinuing therapy. Relapsing disease             
probably represents sarcoidosis that never truly resolved, but which was temporarily suppressed by             
steroid therapy. 
Steroid withdrawal symptoms  
Steroid withdrawal syndrome describes patients who suffer symptoms on steroid withdrawal in the             
presence of normal hypothalamic-pituitary-adrenal (HPA) function. Slow tapering may not prevent           




nausea, and abdominal pain. In contrast to adrenal insufficiency, steroid withdrawal symptoms may             
occur even when dose reduction occurs in the supra-physiological range (>7.5mg prednisolone daily)             
but at these doses patients are not at risk of adrenal crisis. In sarcoidosis it can be challenging to                   
distinguish increasing fatigue or myalgia due to steroid withdrawal from worsening disease, with the              
risk that the steroid dose is increased and patents continue on long term steroids unnecessarily (92,                
148). Steroid withdrawal symptoms are self-limiting and success depends on perseverance with the             
lowest possible steroid dose and then proceeding with a very slow taper over several months (149)                
see Box 2.  
Adrenal insufficiency 
Adrenal insufficiency should always be taken seriously (150). There is considerable individual            
variation in adrenal recovery following steroid treatment, and the dose and duration of therapy are               
poor predictors of subsequent adrenal insufficiency. Generally, long term prednisolone doses ≤7.5            
mg daily are less likely to cause adrenal suppression (151). Biochemical insufficiency detected with a               
cosyntropin (synacthen) suppression test does not necessarily translate into clinical meaningful           





Box 2.  Guide to tapering and withdrawing steroid therapy. 
● Gradually taper steroid dose over months to allow recovery of HPA axis 
● Reduce steroid dose to physiologic range (5-7.5mg prednisolone daily) 
● Reduce prednisolone from 5mg od by 1mg every 2 weeks to 1mg; then 1mg alternate days 
for 2 weeks 
● Stop treatment 
● Warn patient that steroid supplementation with short term steroids may be needed to cover 
illness or surgery for up to 1 year following cessation of therapy 
For a patient with steroid-withdrawal symptoms or suspicion of adrenal insufficiency 
● Consider alternate day therapy or convert to daily hydrocortisone 
● Measure 8-9am cortisol (note cross reactivity of synthetic steroids with cortisol assay). Can 
be performed pre-dose (24h post dose) prednisolone 
● Morning cortisol <100 nmol/L suggests adrenal insufficiency; >450 nmol per litre is 
consistent with adrenal sufficiency. If 100-450 nmol/L consider stimulation test and 
specialist endocrinology referral 
● If cortisol insufficient, maintain on physiological dose with advice to increase dose 2-3x to 
cover injury or illness. After 3 months, perform further adrenal stimulation testing and if 
cortisol sufficient, slowly taper dose. 





Duration of follow-up and discharge 
Patients with Lofgren’s syndrome or stage I chest X-ray can be discharged from medical care once                
resolution is confirmed. More frequent and longer term monitoring is recommended for patients             
with more severe disease and a higher risk of progression (Table 4). Patients in whom steroid                
therapy has been withdrawn are at highest risk of worsening and require the most frequent               
monitoring, particularly during the year after cessation. Patients should not be discharged to primary              
care if there is dangerous or potentially dangerous disease, major ongoing loss of quality of life or                 
the 
patient is still on pharmacological treatment for sarcoidosis. 
Table 4. Guidance for follow-up. Adapted from Valeyre (152) 
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 Frequency Duration Discharge 
Lofgren’s syndrome or 
stage I chest X-ray 
6 monthly 2 years Yes 
Stage II-IV chest X-ray 3-6 monthly or 
Annually (depending 
on clinical suspicion 






Clinical Practice Points 
 
2. No patients on medication should be managed in primary care alone, even stable  
well patients should have hospital monitoring when on treatment. Patients under the long term care 
of their GP should be referred back to a hospital respiratory physician if they develop new or 
worsening symptoms. 
 
2. All patients undergoing active monitoring or treatment should have regular lung function tests as 














2-3 monthly or 
3-6 monthly 
1 year or 




3. A trial of withdrawal of steroid therapy should be performed in most patients with controlled 






7. Communication with patients and expert network referrals 
 
Discussion with patients 
 
Patients with sarcoidosis are eager for information about the cause, prognosis, expected long-term             
course, and treatment options. Online, self-directed searches for information yield an array of             
results, sometimes conflicting, which often provokes anxiety and confusion. Clinicians should clarify            
and help untangle this web of information. However, it can be challenging to convey the disease                
process when the cause remains unknown, and the use of disease phenotype to inform              
prognostication, whilst important, is limited by incomplete data. In addition, the try-and-see            
treatment approach for immunosuppressive therapies, which results in variable and often           
unpredictable outcomes, can be frustrating.  
 
Explaining the disease process of sarcoidosis is not easy. The unknown antigen factor may cause               
reflection on possible environmental or occupational exposures. Yet, there is a dearth of data              
regarding the timing and nature of the sarcoid antigen exposure. In addition, the largely              




unsatisfying disease model. Acknowledging this frustration and leaving space for patient questions            
reflects compassion on behalf of the care provider. Clinicians should also actively signpost further              
sources of information which are directly targeted at patients including those from the British Lung               
Foundation and SarcoidosisUK. 
 
Outcomes in sarcoidosis vary by organ phenotype. The extent and anatomical topography of disease,              
as well as response to treatment, are key prognostic features. Therefore, optimal counselling             
acknowledges data from large scale epidemiology reports but contextualizes results to individual            
factors. For example, emphasising that most patients in pooled cohorts enter remission within a few               
years of diagnosis can be misleading for patients with severe disease, such as aggressive cutaneous               
disease, neurosarcoidosis, or extensive pulmonary involvement; for the latter, the onset of fibrosis             
will especially influence long-term outcomes. In contrast, reported outcomes for cardiac sarcoidosis            
are alarming, yet not all patients experience significant disability or premature death. Many subjects              
in earlier reports were not on treatment or had not undergone screening for an internal cardiac                
defibrillator. For pro-actively managed patients, an individual’s clinical status is a critical determinant             




As sarcoidosis is a dynamic and incurable disease, treatment decision making is a long-term process               
rather than a one-time task. Explaining the triggers for treatment helps patients understand why not               
everyone requires treatment, or why treatment may be indicated long after diagnosis. As reviewed              
in this document, the decision to treat or not is based on the status of disease balanced against                  
possible side effects of therapies. When treatment is warranted, patient counselling should include             
the rationale for a long-term course, including the plan for staged dose adjustments based on               
treatment effect and medication tolerance. The profile of side effects can be overwhelming. A              
printed summary or handout, in simple and easy to read language, for patients to refer to after the                  
visit is invaluable. Side effect monitoring is often labour intensive for the patient and clinical practice                
alike; establishing a mechanism for patients to readily access office staff to report concerns or               
provide testing updates is essential.  
 
When the diagnosis of sarcoidosis is certain (without concern for another environmental or             
occupational disease, such as berylliosis or hypersensitivity pneumonitis) there is no indication for             
patients to change their daily activities for the purpose of improving sarcoidosis. However, medical              




a sedentary lifestyle, pursue a healthy diet and regular exercise, and cease smoking or recreational               
drug use. These interventions help with sarcoidosis-associated fatigue and body aches, mitigate the             
weight-gain risk of systemic steroid treatment, and avoid further lung injury. Referral to a General               
Practitioner for further advice on healthy lifestyle may be helpful for many patients. 
 
Interactions between secondary and tertiary care 
All patients with sarcoidosis, regardless of presenting organ phenotype, should undergo surveillance            
for 
multi-organ disease for at least a few years following the initial diagnosis. Preparing patients for this                
course underscores the chronic disease model of sarcoidosis. Patients with active sarcoidosis are             
typically followed by an expert consultant in a tertiary ILD unit, who can confidently assess the                
diagnosis, and establish treatment and long-term monitoring plans with the support of an expert              
multidisciplinary team. At this point it is crucial that patients have access to specialist respiratory               
nurses who can assist with drug monitoring, managing side effects and help with access to other                





In multi-organ disease, several providers may be involved. Consultants perform organ-specific tests            
to confirm sarcoidosis and to rule out disease mimics. When treatment extends beyond systemic              
immunosuppression, consultants also manage organ specific medications, such as topical treatments           
for cutaneous disease. Sarcoidosis management is complex, particularly for active and multi-system            
disease, and good communication among medical providers is essential. A lead clinician should be              
identified to both the patient and the medical team as the person to supervise care. A robust                 
approach to communication keeps other involved providers informed of important treatment           
decisions and recent test results. In some instances, a consultant appointment may be overwhelming              
for 
patients, and it is not reasonable to assume that they can relay accurate information to other                
providers. It is therefore vital that there is good communication between primary, secondary and              
tertiary care and patients should be offered a shared care approach (i.e. care between centres) if                
they wish and that the infrastructure is available for this. 
 
 





1. Clinicians should consider the possible need for benefits advice, occupational therapy home            
assessment, pulmonary rehabilitation referral as well as GP assistance with palliative care if needed              
e.g. in cases of progressive fibrotic pulmonary sarcoidosis with resulting respiratory failure.  
 
2. All patients should be encouraged to complete an inventory of quality of life measures and as part                  
of this clinicians should emphasise the concept of `self-care` i.e. a deliberate activity that sarcoidosis               
patients undertake to look after their physical, mental or emotional well being 
 
3. There should be good communication between service providers (both between tertiary and             
secondary care, and between different specialists depending on organ involvement) and all patients             




To be completed. 
 
Disclaimer 
A Clinical Statement reflects the expert views of a group of specialists who are well versed on the                  
topic concerned, and who carefully examine the available evidence ​in relation to their own clinical               
practice. A Clinical Statement does not involve a formal evidence review and is not developed in                 




legal documents or a primary source of detailed technical information. Readers are encouraged to              
consider the information presented and reach their own conclusions.  
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